In an exclusive interaction with Business Today, Sharma called the ongoing correction a ‘bear market’, which he said, might ...

Kezar Life Sciences reports positive Phase 2a data for zetomipzomib in autoimmune hepatitis, showing higher response rates and reduced steroid use.